Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug ...

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...

Medtronic reported that the FDA approved the InterStim smart programmer, an app-based platform that assists patients in the long-term management of therapy for overactive bladder or chronic fecal ...

DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global, ...

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...